• Debiopharm is a privately-held Swiss biopharmaceutical company mainly active in development and clinical testing of drug candidates. It was founded in...
    19 KB (1,557 words) - 09:08, 2 October 2024
  • Thumbnail for Triptorelin
    developed by Debiopharm, is launched in two European countries - a new therapeutic avenue for the treatment of sexual deviations". Debiopharm. 23 June 2009...
    14 KB (981 words) - 11:38, 23 March 2024
  • Thumbnail for Grégoire Courtine
    Retrieved 7 October 2020. "Debiopharm Group™ presents the 'Debiopharm Group Life Sciences Award 2013' and two 'Junior Debiopharm Group Life Sciences Awards...
    15 KB (1,219 words) - 16:20, 19 September 2024
  • Daiichi Sankyo (2005– ) Danco (2000– ) Darou Pakhsh (1956– ) Dawa (1994– ) Debiopharm (1979– ) Dechra (1997- ) Delix (2019– ) Dentsply Sirona (1899– ) Dermapharm...
    34 KB (2,175 words) - 10:48, 29 October 2024
  • Thumbnail for Urturn
    Balderton Capital and $2.7 million invested by the private equity arm of Debiopharm Group. Chief executive Stelio Tzonis said that use of the funding will...
    4 KB (356 words) - 11:19, 23 April 2022
  • Thumbnail for Afabicin
    Afabicin (Debio 1450) is an experimental antibiotic developed by Debiopharm for the treatment of Staphylococcus aureus infections. It is a prodrug which...
    4 KB (357 words) - 00:34, 18 October 2024
  • Thumbnail for Life sciences industry in Switzerland
    headquarters Cochlear Limited Basel  Basel-Stadt European headquarters Debiopharm Lausanne  Vaud Global headquarters Edwards Lifesciences Nyon  Vaud European...
    13 KB (690 words) - 19:15, 2 November 2024
  • Thumbnail for Paul Scherrer Institute
    spin-off to date to emerge from PSI. In 2017, the Lausanne-based company Debiopharm licensed the active substance 177Lu-PSIG-2, which was developed at the...
    49 KB (5,912 words) - 04:05, 21 October 2024
  • Thumbnail for Alisporivir
    Alisporivir is under development by Debiopharm for Japan and by Novartis for the rest of the world (licence granted by Debiopharm) since February 2010.[citation...
    7 KB (570 words) - 16:49, 4 February 2024
  • 2024. Debiopharm Group Press Release (November 2010) "Abionic wins the 'Prix Debiopharm Valais pour les Sciences de la Vie", www.debiopharm.com "Abionic...
    14 KB (1,246 words) - 22:58, 5 August 2024
  • Thumbnail for PANACREAS
    Retrieved 30 June 2022. "Start". Lu.se. Retrieved 30 June 2022. "Debiopharm". Debiopharm.com. Retrieved 30 June 2022. [2] [dead link] "ALTA". Altaweb.eu...
    7 KB (536 words) - 06:50, 11 October 2024
  • novel narrow-spectrum antibiotic that is now in clinical development at DebioPharm.  Several other companies have been spun out of his research programs...
    18 KB (2,130 words) - 22:44, 14 August 2024
  • Edwards, Cheryl Arrowsmith and Jack Greenblatt and since acquired by Debiopharm Group for Phase 2 asset based on a novel antibiotic target. Mendlein served...
    5 KB (499 words) - 16:07, 20 September 2023
  • Thumbnail for Jean-Christophe Leroux
    Pharmaceutical Sciences Highly Cited Researcher 2014 - Thomson Reuters Debiopharm Life Sciences Award Steacie Fellowship Controlled Release Society Young...
    11 KB (1,067 words) - 23:09, 30 July 2024
  • Altran - Anecova - Bachem - Bracco - Celgene - Covance - CSL Behring - Debiopharm - Eli Lilly - EspeRare - Ferring Pharmaceuticals - Glenmark Pharmaceuticals...
    6 KB (616 words) - 09:08, 18 July 2024
  • Thumbnail for Peter DeMarco
    therapy beyond his own medical practice. Swiss pharmaceutical company Debiopharm S.A. replied, "Drug induced cell regeneration appears to be a revolutionary...
    13 KB (1,615 words) - 17:13, 8 June 2024